Results 81 to 90 of about 77,174 (152)

Benefit and outcome of using temozolomide-based chemoradiotherapy followed by temozolomide alone for glioblastoma in clinical practice

, 2017
© 2017 Zerbinis Publications. All rights reserved. Purpose: Temozolomide (TEM), an oral alkylating agent, has shown promising activity in the last 10 years in the treatment of glioblastoma multiforme (GBM). Our goal was to show the benefit of concomitant
Djan I., Vidovic V., Salma S., Lučić, Miloš, Vuleković, Petar, Bjelan M., Novaković, Milan   +6 more
core  

Application and advance of temozolomide in the treatment of pituitary adenomas

Chinese Journal of Contemporary Neurology and Neurosurgery, 2015
Pituitary adenoma is a common primary tumor in central nervons system. The aggressive pituitary adenomas show invasive characteristics with higher recurrence rate and worse prognosis, which normally need the comprehensive therapy of surgery ...
Yi-guang LIN, Xiao-min LIU
doaj  

Immunotherapy for Newly Diagnosed Glioblastoma: Current Evidence and Future Perspectives. [PDF]

J Pers Med
Arend RB, Peroni BZ, Lima NL, Cruz Garcia M, Koerich AH, do Nascimento AF, Dos Santos RTF, Tapia K, Kerpel D, Jung GS, Roman A, Gago G, da Silva MBC, Vial ADM, Agosti E.   +14 more
europepmc   +1 more source

Modulating yes-associated protein (YAP) in overcoming temozolomide chemoresistance in glioblastoma

Objective:The Hippo signaling pathway is often dysregulated in cancer. The study aims to investigate whether the Hippo signaling pathway contributes to temozolomide chemoresistance in glioblastoma, and to validate whether the combinational treatment of ...
Leung, Gilberto Ka Kit, Wong, Cheuk Lun, Kiang, Mei Yee Karrie   +2 more
core  

Use of Rucaparib Plus Temozolomide in Advanced Uterine Leiomyosarcoma: A Case Report From a Tertiary Centre in India. [PDF]

Cureus
Arora A, Rastogi S, Tilak A, Ahmed S, Rathore R.   +4 more
europepmc   +1 more source

Translational Theranostics in Glioblastoma: FAPI-46 as a Precision Medicine Tool. [PDF]

J Nucl Med
Jeanjean P, Swaidan A, Tse C, Kwock S, Fajnorova I, Dove R, Azrour IC, Taylor S, Comin-Anduix B, Nathanson DA, Carlucci G, Calais J, Czernin J, Besserer-Offroy É, Mona CE.   +14 more
europepmc   +1 more source

Mature results from EORTC 22033: Implications of inferior results with monotherapy for grade 2 gliomas. [PDF]

Neuro Oncol
Kinslow CJ, Schiff D.
europepmc   +1 more source

Ion Channel-Targeting Modulators in Glioma: Pharmacological Advances and Therapeutic Perspectives. [PDF]

Int J Mol Sci
Wu SN, Lin SC, Liutkevičienė R.
europepmc   +1 more source

Corticotroph Tumour Progression 37 Years After Bilateral Adrenalectomy with Temozolomide-Naive Response to Pembrolizumab. [PDF]

Endocr Oncol
Mignone E, Ephraums L, Chapman I, Quick E, De Sousa SMC, Ho J.   +5 more
europepmc   +1 more source

Temozolomide and olaparib for the treatment of an ARID1A-mutated uterine carcinosarcoma: A case report. [PDF]

Gynecol Oncol Rep
Liu C, Abozenah Y, Rutherford TJ, Andikyan V, Kohut A, Anderson ML.   +5 more
europepmc   +1 more source